Physician profile
Techsin T Ty
NPI 1992705156
$11,092.08
in general payments reported to CMS, 2019-2025
51 companies · $2,057 in 2025
The $2,057 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,038 · 2020: $378 · 2022: $3,272 · 2023: $1,821 · 2024: $1,525 · 2025: $2,057.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,377 · Education: $25.77.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,377.26 |
| Education | $25.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,775.86 | 2019-2025 | Vraylar, Ubrelvy, Linzess |
| Astrazeneca Pharmaceuticals Lp | $1,682.59 | 2019-2025 | Farxiga, Airsupra, Fasenra |
| Novo Nordisk INC | $1,225.93 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $542.11 | 2019-2025 | Repatha, Otezla, Repatha |
| Pfizer INC. | $533.18 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $525.97 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $387.91 | 2022-2025 | Rexulti |
| Lilly USA, LLC | $383.95 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novartis Pharmaceuticals Corporation | $283.22 | 2019-2024 | |
| Mallinckrodt Enterprises LLC | $240.80 | 2019 | |
| Janssen Pharmaceuticals, INC | $226.11 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $203.32 | 2022-2025 | Jardiance |
| Glaxosmithkline, LLC. | $193.28 | 2019-2025 | Shingrix, Trelegy Ellipta |
| Dexcom, INC. | $97.23 | 2022-2025 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $96.58 | 2019-2020 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Techsin Ty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.